VANCOUVER, British Columbia , May 19, 2020 — NewLeaf Brands Inc. (NLB.CN) (OTC: NLBIF) (0NF.F) (“NewLeaf Brands” or the “Company“) is pleased to announce that its wholly-owned subsidiary, Mydecine Group (“Mydecine”) is working to build an ecosystem of resources targeted at unlocking the potential of fungi for human wellness. Through a combination of traditional medicine knowledge and modern scientific inquiry, Mydecine strives to bring the public products that will aid them in their journey to personal wellness.
Core to this potential are psilocybin producing mushrooms. In recent times, psilocybin and other tryptamines have begun to experience a well-deserved upsurge in medical interest; Mydecine believes in nurturing this potential. Utilizing various research partnerships, university collaborations and public advocacy groups, Mydecine has a clear path, leading to safe and effective use of fungal compounds for human health.
“With the growing public interest in mushroom applications for human health, Mydecine’s lab in Denver stands ready to provide the consumers with the information and innovation they desire,” proclaimed Rob Roscow , CSO, NewLeaf Brands, Inc.
Fungi contain a wealth of compounds provided to us by nature and Mydecine is more than excited to announce the build out of a specialty mycology lab in Denver, Colorado . The lab will serve Mydecine’s needs for the study, selection and cultivation of valuable and rare fungal products and will incorporate state of the art analytical chemistry, molecular biology, next-gen sequencing, and tissue culture. Mydecine believes that this potential in fungi is barely tapped in our society and that this lab will facilitate its efforts to bring the highest quality fungal food and wellness products to the public.
The capabilities of this lab will serve as a cornerstone for Mydecine’s research and development efforts. Additionally, work at this lab will both enable and support numerous research partnerships. The lab build out will allow immediate inquiry into improved production of mushroom products as functional foods, while supporting licensed research partners in the parallel study of psychedelic mushroom compounds for treatment of mental health and other serious conditions.
About NewLeaf Brands
NewLeaf Brands Inc. is the parent company operating innovative product divisions in the Naturally Sourced Therapies (NST) space. While controlling a variety of Psilocybin and hemp-derived CBD brands that design, manufacture and distribute cutting edge products, NewLeaf Brands Inc. further enhances its portfolio with numerous cultivation properties, retail locations, and other land assets.
NewLeaf Brands Inc. is the progressive and innovative Naturally Sourced Therapies (NST) lifestyle group known around the globe. Focusing on the rapidly emerging psilocybin and psychedelic medicines market, the Company’s wholly-owned subsidiary 1220611 B .C. Ltd. (operating as Mydecine Group) (“Mydecine”) is a vertically integrated company engaged to utilize the vast medicinal, health and wellness capabilities of the various compounds found in mycology as a whole. Established to parallel the early emergence of the industry, Mydecine aims to be a pioneer in the cultivation, processing, product development, and research and development of mycology’s exciting compounds through its three divisions, “Mydecine Farms,” “Mydecine Wellness” and “Mydecine Labs.” Furthermore, the Company’s wholly-owned subsidiaries in the hemp-derived CBD space, We are Kured LLC, Drink Fresh Water LLC, Relyfe Brand LLC, Fresh Water CBD LLC and TeaLief Brand LLC have quickly developed into market leaders and maintain extensive retail and cultivation land investments in the United States .
For further information about NewLeaf Brands, please consult the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.NABrandsInc.com. For further information about We Are Kured, please visit their website at www.wearekured.com.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, but not limited to completion of planned improvements at both the Canadian and US sites on schedule and on budget, the availability of financing needed to complete the Company’s planned improvements on commercially reasonable terms, planned occupancy by the tenant-growers, commencement of operations, differences in yield on expected harvests, delays in obtaining statutory approval for marijuana production plans, issues that may arise throughout the grow period, outdoor crops affected by weather, the ability to mitigate the risk of loss through appropriate insurance policies, and the risks presented by federal statutes that may contradict local and state legislation respecting legalized marijuana. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
This news release does not constitute an offer of securities for sale in the United States . These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.
On Behalf of the Board of Director
Chief Executive Officer
We Are Kured Contact:
Founder & CEO
For Further Information Contact:
View original content:http://www.prnewswire.com/news-releases/newleaf-brands-wholly-owned-subsidiary-mydecine-group-is-working-to-build-an-ecosystem-of-resources-targeted-at-unlocking-the-potential-of-fungi-for-human-wellness-301061377.html
SOURCE NewLeaf Brands Inc.
View original content: http://www.newswire.ca/en/releases/archive/May2020/19/c4218.html